Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study

Ralf W. Dittmann (Lead / Corresponding author), Esther Cardo, Peter Nagy, Colleen S. Anderson, Ralph Bloomfield, Beatriz Caballero, Nicholas Higgins, Paul Hodgkins, Andrew Lyne, Richard Civil, David Coghill

    Research output: Contribution to journalArticle

    57 Citations (Scopus)

    Abstract

    The aim of this study was to compare the efficacy and safety of the prodrug psychostimulant lisdexamfetamine dimesylate (LDX) and the non-stimulant noradrenergic compound atomoxetine (ATX) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who had previously responded inadequately to methylphenidate (MPH).
    Original languageEnglish
    Article numbern/a
    Number of pages12
    JournalCNS Drugs
    Volumen/a
    DOIs
    Publication statusPublished - 20 Aug 2013

    Fingerprint Dive into the research topics of 'Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study'. Together they form a unique fingerprint.

    Cite this